Clinical Trials

Multiple clinical trials evaluate the therapeutic applications of imidazole derivatives across diverse therapeutic areas, ranging from Phase 1 safety and pharmacokinetic evaluations to non-interventional studies. These investigations target newly diagnosed glioblastoma (sponsored by Double Bond Pharmaceutical AB), relapsed or unresectable leiomyosarcoma (PTC Therapeutics), and metabolic modulation in type 2 diabetes (Assistance Publique - Hôpitaux de Paris). Recruitment statuses across registry records range from completed interventions to studies that are not yet recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04967690 Not yet recruiting
Newly Diagnosed Glioblastoma
Double Bond Pharmaceutical AB
2024-01 Phase 1
NCT03761095 Completed
Leiomyosarcoma
PTC Therapeutics
2019-03-13 Phase 1
NCT03732690 Completed
Type 2 Diabetes
Assistance Publique - Hôpitaux de Paris|ICAN Nutrition Education and Research
2018-12-05 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Imidazole product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Imidazole binds to metal cofactors or key catalytic residues within essential enzymes, blocking downstream biochemical signaling cascades and disrupting critical cellular metabolic processes. This targeted enzymatic inhibition halts pathological cell proliferation and metabolic dysfunction, providing therapeutic rationale for its investigation in oncological indications like glioblastoma and leiomyosarcoma, as well as metabolic conditions such as type 2 diabetes.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.